Learn About Adenosine Monophosphate Deaminase Deficiency

What is the definition of Adenosine Monophosphate Deaminase Deficiency?

Adenosine monophosphate (AMP) deaminase deficiency is a condition that can affect the muscles used for movement (skeletal muscles). In many affected individuals, AMP deaminase deficiency does not cause any symptoms. People who do experience symptoms typically have fatigue, muscle pain (myalgia), or cramps after exercise or prolonged physical activity (exercise intolerance). Following strenuous activity, they often get tired more quickly and stay tired longer than would normally be expected. In rare cases, affected individuals have more severe symptoms including severe muscle weakness, low muscle tone (hypotonia), and muscle wasting (atrophy), but it is unclear whether these symptoms are due solely to AMP deaminase deficiency or additional health conditions. Exercise intolerance associated with AMP deaminase deficiency usually becomes apparent in childhood or early adulthood.

Save information for later
Sign Up
What are the causes of Adenosine Monophosphate Deaminase Deficiency?

AMP deaminase deficiency is caused by mutations in the AMPD1 gene, which provides instructions for producing an enzyme called AMP deaminase. This enzyme is found in skeletal muscles, where it plays a role in producing energy. Skeletal muscle cells need energy to function and move the body.

How prevalent is Adenosine Monophosphate Deaminase Deficiency?

AMP deaminase deficiency is one of the most common inherited muscle disorders in white populations, affecting 1 in 50 to 100 people. The prevalence is lower in African Americans, affecting an estimated 1 in 40,000 people, and the condition is even less common in the Japanese population.

Is Adenosine Monophosphate Deaminase Deficiency an inherited disorder?

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Who are the top Adenosine Monophosphate Deaminase Deficiency Local Doctors?
Elite
Highly rated in
2
conditions

Medical University Of Gdansk

Gdansk, PM, PL 

Iwona Rybakowska is in Gdansk, Poland. Rybakowska is rated as an Elite expert by MediFind in the treatment of Adenosine Monophosphate Deaminase Deficiency. She is also highly rated in 2 other conditions, according to our data. Her top areas of expertise are Adenosine Monophosphate Deaminase Deficiency, Alcoholic Ketoacidosis, Myasthenia Gravis, and Heavy Metal Poisoning.

Elite
Highly rated in
1
conditions

Federal University Of Fronteira Sul

Chapeco, SC, BR 

Andreia Cardoso is in Chapeco, Brazil. Cardoso is rated as an Elite expert by MediFind in the treatment of Adenosine Monophosphate Deaminase Deficiency. She is also highly rated in 1 other condition, according to our data. Her top areas of expertise are Adenosine Monophosphate Deaminase Deficiency, Hypertension, Abdominal Obesity Metabolic Syndrome, and Memory Loss.

 
 
 
 
Learn about our expert tiers
Learn more
Distinguished
Highly rated in
10
conditions

Universidade Federal De Santa Maria

Santa Maria, RS, BR 

Matheus Baldissera is in Santa Maria, Brazil. Baldissera is rated as a Distinguished expert by MediFind in the treatment of Adenosine Monophosphate Deaminase Deficiency. He is also highly rated in 10 other conditions, according to our data. His top areas of expertise are Adenosine Monophosphate Deaminase Deficiency, Streptococcal Group B Infection, Fascioliasis, and Strep Throat.

What are the latest Adenosine Monophosphate Deaminase Deficiency Clinical Trials?
Match to trials
Find the right clinical trials for you in under a minute
Get started
Who are the sources who wrote this article ?

Published Date:updated Last, July

Published By: National Institutes of Health

What are the Latest Advances for Adenosine Monophosphate Deaminase Deficiency?
A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin.
Tired of the same old research?
Check Latest Advances